Measuring Frailty in Patients Being Treated for Multiple Myeloma

Clinical Pearls Podcasts published on July 17, 2017
Download Transcript Download Podcast
R. Donald Harvey, III, PharmD, BCOP, FCCP, FHOPA
Associate Professor
Department of Pharmacology
Department of Hematology and Medical Oncology
Emory University School of Medicine
Director, Phase I Clinical Trials Section
Winship Cancer Institute of Emory University
Atlanta, Georgia

Measuring Frailty in Patients Being Treated for Multiple Myeloma
  • Multiple methods for assessing the frailty of elderly patients with multiple myeloma
    • Frailty assessment important for identifying optimized multiple myeloma treatments and regimens to fit both the individual’s disease and degree
      of fitness
  • Measures of frailty to assess patients and their ability to tolerate treatment
    • Performance status
    • Age may not be an effective measure of frailty alone but is certainly a factor to be considered
    • The 2-minute walk test: the duration of distance that the patient may be able to walk over a 2-minute period
    • The time it takes for a patient to get up and out of the chair
  • Frailty measures more commonly used in the geriatric population but certainly have a role within our patients here with myeloma
    • Patients over the age of 80 may be at higher risk for increasing frailty
    • May be unable to tolerate more aggressive treatment, either in terms of dose or number of drugs prescribed
Last modified: June 16, 2017
Related Items by Author
Optimal Pre-medication Strategy for Daratumumab
R. Donald Harvey, III, PharmD, BCOP, FCCP, FHOPA
Clinical Pearls Podcasts published on July 3, 2017
Rash Management for Patients Taking IRd (Ixazomib-Lenalidomide-Dexamethasone)
R. Donald Harvey, III, PharmD, BCOP, FCCP, FHOPA
Clinical Pearls Podcasts published on June 19, 2017
How do I manage diarrhea in my patients taking ixazomib?
R. Donald Harvey, III, PharmD, BCOP, FCCP, FHOPA
Clinical Pearls Podcasts published on January 30, 2017
What prophylactic antithrombotic agents are safe to use with lenalidomide?
R. Donald Harvey, III, PharmD, BCOP, FCCP, FHOPA
Clinical Pearls Podcasts published on January 16, 2017
How do I manage renal dysfunction in my patient who is taking lenalidomide?
R. Donald Harvey, III, PharmD, BCOP, FCCP, FHOPA
Clinical Pearls Podcasts published on January 3, 2017
What do I do if my patient has an infusion reaction at home after receiving daratumumab?
R. Donald Harvey, III, PharmD, BCOP, FCCP, FHOPA
Clinical Pearls Podcasts published on December 19, 2016
What do I do if my patient has an infusion reaction on elotuzumab, even after premedication?
R. Donald Harvey, III, PharmD, BCOP, FCCP, FHOPA
Clinical Pearls Podcasts published on December 14, 2016 in Podcasts